	Metastatic prostate cancer in the genomic era: Guideline-concordant strategies for diagnosis, treatment, and survivorship. J Am Assoc Nurse Pract Connors LM. PMID: 41770148 [PubMed - in process]
	Metastatic Clear Cell Renal Cell Carcinoma Identified in a Gastric Biopsy: Diagnostic Recognition in an Unusual Site. Cureus Nikolaus Y, Sigdel S. PMID: 41769517 [PubMed]
	Inhibition of Castration-Sensitive LNCaP, Castration-Resistant TRAMP-C2, and Bone-Metastatic C4-2B Prostate Cancer Cell Growth by an Alpha-Tomatine Tomato Extract: In Vitro and In Vivo Study. Cureus Takeda S, Uehara M, Yurube T, Ueda S, Shigemura K. PMID: 41769483 [PubMed]
	Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate Cancer. Eur Urol Open Sci Mehra N, Oprea-Lager DE, van de Luijtgaarden ACM, van der Voort van Zyp JRN, Aluwini S, Stoevelaar HJ, van den Bergh RCN, APCCC-NL panel. PMID: 41768772 [PubMed]
	Identifying Prognostic Biomarkers and Key Pathways in Renal Clear Cell Carcinoma: A Pilot Study Using Integrated miRNA and Gene Expression Analysis. Biochem Res Int Manoochehri H, Mirzaee K, Taherkhani A, Gholyaf M. PMID: 41768422 [PubMed]
	Computational pathology in bladder cancer: A scoping review. Bladder Cancer Superdock M, Wobker SE, Carmicheal I, Kim WY. PMID: 41768416 [PubMed]
	KLS-3021, a multifunctional oncolytic virus, demonstrates potent early-intervention efficacy in preclinical models of prostate-confined and locally advanced prostate cancer. Front Oncol Seo J, Park K, Lee S, Kang H, Kim J, Lee E, Shin J, Hong SO, Kim S, Kim SJ. PMID: 41768263 [PubMed]
	The diagnostic value of radiomics-based machine learning for lymph node metastasis in prostate cancer: a systematic review and meta-analysis. Front Oncol Liu Z, Yang Y, Guan X. PMID: 41768254 [PubMed]
	Machine learning approaches for predicting progression in hormone-sensitive prostate cancer patients. Front Oncol Zhu B, Jiang H, Zhang C, Wang Q, Yang L, Yang H, Li R, Li J, Pang X, Zheng Y, Yan L, Wang Y, Bai Y. PMID: 41768252 [PubMed]
	Exploring treatment models for oligometastatic castration-sensitive prostate cancer: evolution of therapeutic strategies. Front Oncol Xu H, Guo J, Peng W, Wang J, Shi L, Yang X. PMID: 41768233 [PubMed]
	Low yield of pathological lymph node metastasis among patients with invasive penile squamous cell carcinoma in the context of high HIV burden: evidence from a prospective cohort study in Zambia. Front Urol Mapulanga V, Ngalamika O, Mumba C, Muhimbe Z, Pettaway CA, Bowa K, Sinkala E. PMID: 41767588 [PubMed]
	Clinically oriented immune heterogeneity in prostate cancer: emerging targets and strategies. Front Immunol Zhan M, Zhao B, Wu J, Li K, Chen Y, Chen H, Zhao L, Zhu J. PMID: 41766852 [PubMed - in process]
	Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025. Asia Pac J Clin Oncol Chiong E, Eapen R, Buchan N, Chen K, Hakim L, Hamid AR, Joung JY, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Mallick I, Ng CF, Ngam PI, Ong TA, Pang J, Poon DMC, Roberts N, Saad M, Sakamoto S, Tey J, Thang SP, Toh PC, Türkeri L, Vinh NT, Wong A, Zhu Y, ANZUP Cancer Trials Group, Davis ID. PMID: 41766356 [PubMed - as supplied by publisher]
	Integrated scRNA-seq and bulk transcriptomics identify an amino acid metabolism-associated prognostic signature and highlight FUS as a potential driver in prostate cancer progression. Funct Integr Genomics Yuan J, Shen D, Pan Z, Lv F, Zhao Y, Zheng W, Yin Q, Wu L, Yu J, Xu C, He Q, Pan H. PMID: 41766003 [PubMed - in process]
	Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. Lancet Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia JA, Brown JR, Rettig MB, Singer AE, Reiter RE, Eggener S, Brisbane W, Roy S, Zaorsky NG, Jia AY, Ma TM, Nickols NG, Efstathiou JA, Mohamad O, Dignam JJ, Seiferheld WF, Pollack A, Sandler HM, Nguyen PL, Pommier P, Spratt DE. PMID: 41765025 [PubMed - as supplied by publisher]
	The Hippo pathway in clear cell renal cell carcinoma (ccRCC): a nexus with the VHL disruption? Transl Oncol Waeckel T, Lefranc R, Waeckel M, Riffet M, Tillou X, Levallet G, Bazille C. PMID: 41764979 [PubMed - as supplied by publisher]
	Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study. Urol Oncol Moinard-Butot F, Barbe-Richaud JB, Baudry E, Pierard L, Amrane K, Maillet D, Barthélémy P. PMID: 41764970 [PubMed - as supplied by publisher]
	A phase II study evaluating pharmacokinetics and dosimetry of (177)Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer. EJNMMI Res Shi H, Guo J, Fan W, Li Y, Huang R, Dong Q, Yang Z, Yang Y, Wang X, Gu D, Huo L, Ji Z, Wang F, Xu D, Jiang Z, Li H, Li J, Li R, Qi L, Wang J, Ye D. PMID: 41764712 [PubMed - as supplied by publisher]
	Regulatory roles of microRNAs in signaling pathways and their biomarker potential in prostate cancer. Cancer Cell Int Kalarestaghi H, Amani N, Shoorei H. PMID: 41764450 [PubMed - as supplied by publisher]
	The impact of different exercise modes on prostate cancer: a Bayesian network meta-analysis. Sci Rep Liu J, Li Q, Han Y. PMID: 41764301 [PubMed - as supplied by publisher]

Articles 1 - 20 / 176385

Page 1 of 8820



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy